Ashley C. Gould has over two decades of professional experience, during which she has been a member of executive teams of private and public companies in the technology and life sciences fields, advisor to emerging companies as well as investment funds and a member of not-for-profit boards.
As a trusted advisor to boards of directors, Ms. Gould addressed a large number of issues, including matters related to fiduciary duties of board members, management compensation, congressional investigations, governance issues and audit committee matters. She has a thorough grasp of the many issues confronting corporate boards of directors and substantial experience evaluating and addressing those issues. As an advisor, Ms. Gould evaluates prospective investments by several funds as well as provides direct guidance to companies in their growth stages.
At JUUL Labs, Inc., a private company, Ms. Gould acted as a corporate representative for the company during a period of intense public scrutiny in press interviews, testifying before the House Committee on Energy & Commerce, Subcommittee on Oversight & Investigation as well as in litigation matters. Ms. Gould also developed the company’s nascent corporate responsibility function, while dramatically increasing a number of departments during the company’s rapid growth, including scientific and legal, the latter with a substantial focus on intellectual property.
As a member of the management team at Raptor Pharmaceuticals, a Nasdaq-listed company, Ms. Gould partnered with her executive team colleagues on strategic planning, ran the legal function and was integrally involved in the sale of the company. She also led several administrative functions, including healthcare compliance and government affairs.
During her tenure at Hyperion Therapeutics, also a Nasdaq listed company, Ms. Gould oversaw major corporate transactions, including an acquisition and the ultimate sale of the company. At Hyperion Ms. Gould was extensively involved in product quality and supply chain management and managed the successful resolution of significant litigation against the company.
While at 23andMe, a private company, Ms. Gould successfully led the company through four rounds of venture capital financing. She also testified before the Congressional Energy and Commerce Committee on the subject of direct-to-consumer genetic testing and subsequently initiated and ran the company’s government affairs program as well as the human resources, communications, regulatory affairs and laboratory operations departments.
Ms. Gould has substantial experience identifying and grappling with the difficult and varied issues facing companies operating in the technology, pharmaceutical and medical device fields. She uses her professional training, experience through bet the company circumstances and cutting-edge initiatives to assess issues confronting companies from a business, regulatory, compliance and legal perspective.
Ms. Gould started her career at Wilson Sonsini Goodrich & Rosati PC in Palo Alto, California. She graduated in the top 10 percent of her class from the University of San Francisco School of Law, where she now sits on the Board of Governors, and with a Bachelor of Science from the University of California at Berkeley.